Scioderm Obtains $20,000,000 Series B Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=41f59981-9b47-4be8-938f-dc3247e75391
Date 12/19/2014
Company Name Scioderm
Mailing Address 1007 Slater Road Durham, NC 27703 USA
Company Description The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
Proceeds Purposes The proceeds will be used to fund the development of ZorblisaTM (SD-101), a proprietary topical therapy being developed for the treatment of all patients with Epidermolysis Bullosa (EB), through completion of the US and EU clinical registration programs.